Candriam S.C.A. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 172 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.12 and the average weighting 0.3%.

Quarter-by-quarter ownership
Candriam S.C.A. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$12,649,586
-3.2%
331,141
-8.6%
0.09%
-4.3%
Q2 2023$13,062,498
-6.6%
362,143
-9.0%
0.09%
-3.1%
Q1 2023$13,988,451
-62.3%
397,950
-39.0%
0.10%
-61.2%
Q4 2022$37,114,245
+43.6%
652,302
-0.2%
0.25%
+37.4%
Q3 2022$25,847,000
+0.9%
653,675
+12.2%
0.18%
-13.7%
Q2 2022$25,628,000
-8.8%
582,497
-17.4%
0.21%
+10.5%
Q1 2022$28,114,000
-0.8%
705,006
-0.0%
0.19%
+5.5%
Q4 2021$28,352,000
-0.1%
705,079
+1.0%
0.18%
-6.2%
Q3 2021$28,393,000
+13.9%
697,979
+27.2%
0.19%
+12.9%
Q2 2021$24,927,000
-17.2%
548,930
-25.2%
0.17%
-31.9%
Q1 2021$30,102,000
-3.9%
733,742
-0.0%
0.25%
+1.2%
Q4 2020$31,339,000
+14.0%
733,754
-29.9%
0.25%
-3.9%
Q3 2020$27,500,000
+2.9%
1,046,472
+5.0%
0.26%
-8.5%
Q2 2020$26,727,000
+89.1%
996,878
+22.3%
0.28%
+79.6%
Q1 2020$14,131,000
-2.2%
815,319
+0.0%
0.16%
+1.3%
Q4 2019$14,455,000
+44.0%
815,272
+26.0%
0.16%
+16.5%
Q3 2019$10,036,000
-3.8%
647,079
+6.1%
0.13%
+2.3%
Q2 2019$10,435,000
+9.7%
610,079
+3.3%
0.13%
+6.6%
Q1 2019$9,509,000
+134.7%
590,579
+113.2%
0.12%
+96.8%
Q4 2018$4,052,000
+39.4%
277,000
+73.1%
0.06%
+59.0%
Q3 2018$2,907,000
+17.2%
160,000
+8.8%
0.04%0.0%
Q2 2018$2,480,000
+3.8%
147,000
+20.5%
0.04%
-4.9%
Q1 2018$2,390,000
-13.2%
122,000
-10.3%
0.04%
-14.6%
Q4 2017$2,755,000
-0.3%
136,000
-14.5%
0.05%0.0%
Q3 2017$2,762,000
-11.0%
159,000
-34.3%
0.05%
-17.2%
Q2 2017$3,103,000
+10.3%
242,000
+11.5%
0.06%
+7.4%
Q1 2017$2,812,000
-16.3%
217,000
-36.2%
0.05%
-29.9%
Q4 2016$3,359,000
+6.1%
340,000
+29.8%
0.08%
+1.3%
Q3 2016$3,165,000
+81.6%
262,000
+29.7%
0.08%
+68.9%
Q2 2016$1,743,000
-20.2%
202,000
-12.9%
0.04%
-18.2%
Q1 2016$2,185,000
-42.8%
232,000
+5.2%
0.06%
-46.1%
Q4 2015$3,823,000
+119.6%
220,600
+70.2%
0.10%
+137.2%
Q3 2015$1,741,000
-46.1%
129,600
-9.4%
0.04%
-35.8%
Q2 2015$3,229,000
-27.1%
143,000
-53.9%
0.07%
-24.7%
Q1 2015$4,428,000
+61.0%
310,000
+8.8%
0.09%
+56.1%
Q4 2014$2,750,000285,0000.06%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2017
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders